DIKUL - logo
Narodna in univerzitetna knjižnica, Ljubljana (NUK)
Naročanje gradiva za izposojo na dom
Naročanje gradiva za izposojo v čitalnice
Naročanje kopij člankov
Urnik dostave gradiva z oznako DS v signaturi
  • Treatment of chronic lymphocytic leukaemia and low-grade non Hodgkin's lymphomas with fludarabine = Zdravljenje kronične limfocitne levkemije in ne-Hodgkinovih limfomov s fludarabinom
    Rozman, Ciril
    Fludarabine belongs to the new generation of purine analogues, used for the therapy of chronic lymphoproliferative disorders. In chronic lymphocytic leukaemia (CLL) fludarabine can bring about a ... remission in more than 70% of previously untreated patients, with more than 25% achieving a complete remission. These figures are lower in relapsing or resistant CLL. Fludarabine is more activite than either chlorambucil or the combination of cyclophosphamide, doxorubicin and prednisone (CAP). It is still unclear whether this higher activity will be translated into longer survival. In non-Hodgkin's lymphoma (NHL), fludarabine is active chiefly in low-grade types, in which remission rates of about 60% have been achieved in predominantly pretreated patients. There is growing experience with the use offludorabine as part of combination therapy both in CLL and low-grade NHL. This drug can be combined with adriamycin, mitoxantrone, cyclophosphamide or glucocorticoids. Generally, higher response rates are achieved with combination therapy than with fludarabine alone. The most important side-effects are myelosuppression, immunosupression characterized by a severe and long-lasting depletin of CD4+ T lymphocytes, autoimmune haemolytic anaemiaand transfusion-associated graft-versus-host disease. Fludarabine aloneor in combination with other agents should be considered as first line therapy when the aim i sto cure the underlying condition, e.g. in young patients with aggressive disease in whom chemotherapy is followed by bone marrow transplantation. In other situations, fludarabine is still, an experimental drug, whose definitive place will be determined from ongoing randomized trials.
    Vir: Zdravniški vestnik : glasilo Slovenskega zdravniškega društva = Slovenian medical journal = journal of Slovenian Medical Association. - ISSN 1318-0347 (Letn. 67, supl. 1, maj 1998, str. I-5-I-8)
    Vrsta gradiva - članek, sestavni del
    Leto - 1998
    Jezik - angleški
    COBISS.SI-ID - 7936473

Vnos na polico